[
  {
    "date": "2023-03-31",
    "symbol": "PRTG",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentperiodenddate": "2023-03-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2022,
    "currentfiscalyearenddate": "--03-31",
    "entityfilenumber": "001-40086",
    "entityregistrantname": "Portage Biotech Inc.",
    "entitycentralindexkey": 1095435,
    "entityincorporationstatecountrycode": "A6",
    "entityaddressaddressline1": "Clarence Thomas Building",
    "entityaddressaddressline2": "P.O. Box 4649",
    "entityaddressaddressline3": "Road Town",
    "entityaddresscityortown": "Tortola",
    "entityaddressstateorprovince": "CT",
    "entityaddresscountry": "VG",
    "entityaddresspostalzipcode": "VG1110.",
    "cityareacode": 203,
    "localphonenumber": 221.7378,
    "security12btitle": "Ordinary Shares, no par value",
    "tradingsymbol": "PRTG",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityshellcompany": "false",
    "contactpersonnelname": "Ian Walters",
    "documentfinstmterrorcorrectionflag": "false",
    "auditorfirmid": 688,
    "auditorname": "Marcum LLP",
    "auditorlocation": "Melville, NY",
    "cashandcashequivalents": 10545000,
    "tradeandothercurrentreceivables": 2689000,
    "convertiblenotereceivable": 442000,
    "currentassets": 13676000,
    "investmentsinsubsidiariesjointventuresandassociates": 806000,
    "investmentproperty": 2087000,
    "goodwill": 538000,
    "inprocessresearchanddevelopment": 81683000,
    "deferredcommitmentfee": 839000,
    "otherassets": 38000,
    "noncurrentassets": 85453000,
    "assets": 99129000,
    "tradeandothercurrentpayables": 1865000,
    "currentliabilities": 1865000,
    "deferredtaxliabilities": 10564000,
    "deferredpurchasepricepayabletarus": 7179000,
    "deferredobligationioxmilestone": 4126000,
    "noncurrentliabilities": 21869000,
    "liabilities": 23734000,
    "issuedcapital": 218782000,
    "otherreserves": 21204000,
    "accumulatedothercomprehensiveincome": -4325000,
    "retainedearnings": -159616000,
    "equityattributabletoownersofparent": 76045000,
    "noncontrollinginterests": -650000,
    "equity": 75395000,
    "equityandliabilities": 99129000,
    "researchanddevelopmentexpense": 8214000,
    "generalandadministrativeexpense": 8361000,
    "profitlossfromoperatingactivities": -16575000,
    "changeinfairvalueofdeferredpurchasepricepayabletarusanddeferredobligationioxmilestone": 2711000,
    "impairmentlossioxiprd": -59320000,
    "impairmentlosstarusiprd": -4585000,
    "impairmentlossgoodwill": -43862000,
    "impairmentlossstimunity": -818000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -260000,
    "gainslossesonchangeinfairvalueofwarrants": 33000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -53000,
    "depreciationandamortisationexpense": 1000,
    "revenuefrominterest": 217000,
    "interestexpense": 9000,
    "profitlossbeforetax": -122522000,
    "incometaxexpensecontinuingoperations": -17856000,
    "profitloss": -104666000,
    "netunrealizedlossoninvestments": -5283000,
    "comprehensiveincome": -109949000,
    "profitlossattributabletoownersofparent": -104611000,
    "profitlossattributabletononcontrollinginterests": -55000,
    "comprehensiveincomeattributabletoownersofparent": -109894000,
    "basicanddilutedearningslosspershare": -6.49,
    "weightedaveragessharesoutstandingbasicanddiluted": 16119000,
    "numberofsharesoutstanding": 17606,
    "shareissuerelatedcost": 90000,
    "sharesissuedoraccruedforservices": 120000,
    "sharesissuedoraccruedforservicesshares": 20,
    "increasedecreasethroughsharebasedpaymenttransactions": 4276000,
    "sharesissuedintarusacquisition": 17200000,
    "sharesissuedintarusacquisitionshares": 2426,
    "sharesissuedinioxexchange": 9737000,
    "sharesissuedinioxexchangeshares": 1070,
    "deferredobligationioxmilestones": -5478000,
    "excessofnoncontrollinginterestacquiredoverconsiderationiox": 29609000,
    "sharesissuedtolincolnforcommitmentfeeundercommittedpurchaseagreement": 900000,
    "sharesissuedtolincolnforcommitmentfeeundercommittedpurchaseagreementshares": 94,
    "sharesissuedunderatm": 944000,
    "sharesissuedunderatmshares": 167,
    "purchaseofsharesissuedundercommittedpurchaseagreement": 2038000,
    "purchaseofsharesissuedundercommittedpurchaseagreementshares": 480,
    "adjustmentsforsharebasedpayments": 4276000,
    "impairmentloss": 59320000,
    "changeinfairvalueofdeferredspurchasepricepayabletarusanddeferredobligationioxmilestone": -2711000,
    "increasedecreaseindeferredtaxliabilityasset": -17881000,
    "gainlossonhedgeineffectiveness": 260000,
    "lossincomeonfairvalueofwarrantliability": -33000,
    "fairvalueofstockissuedforservices": 120000,
    "netforeignexchangelosses": -14000,
    "adjustmentsfordepreciationandamortisationexpense": 1000,
    "increasingdecreasingaccountsreceivable": -31000,
    "adjustmentsfordecreaseincreaseinprepaidexpenses": -1201000,
    "adjustmentsfordecreaseincreaseinotherassets": 24000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 1114000,
    "adjustmentsforincreasedecreaseinotherliabilities": 84000,
    "cashflowsfromusedinoperatingactivities": -12073000,
    "purchaseofconvertiblenotereceivable": 614000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 3000,
    "cashflowsfromusedininvestingactivities": -617000,
    "repaymentofnotespayableassumedintarusacquisition": 2000000,
    "repaymentofmilestoneobligationassumedintarusacquisition": 1009000,
    "proceedsfromsharesissuedunderatmandcommittedpurchaseagreement": 2982000,
    "paymentsforshareissuecosts": 90000,
    "cashflowsfromusedinfinancingactivities": -117000,
    "increasedecreaseincashandcashequivalents": -12807000,
    "fairvalueofsharesissuedfortarus": 17200000,
    "fairvalueofsharesissuedfornoncontrollinginterestpurchaseofiox": 9737000,
    "fairvalueofdeferredpurchasepricepayabletarus": 8538000,
    "fairvalueofdeferredobligationioxmilestone": 5478000,
    "liabilitiesassumedintarusacquisition": 3000000,
    "fairvalueofsharesissuedforcommitmentfeescommittedpurchase": 900000,
    "netunrealizedlossoninvestmentsinintensityandstimunityconvertiblenote": -5283000,
    "percentageofvotingequityinterestsacquired": 0.07,
    "proportionofownershipinterestinsubsidiary": 0.7,
    "cash": 10500000,
    "totalcurrentliabilities": 1900000,
    "netlossincome": 104700000,
    "cashusedinoperatingactivities": 12100000,
    "proportionofownershipinterestsheldbynoncontrollinginterests": 0.3,
    "antidilutiveeffectonlosspershare": 1963420,
    "currentreceivablesfromsaleofproperties": 1653000,
    "currentadvancestosuppliers": 621000,
    "researchanddevelopmentcredit": 169000,
    "taxdeposits": 119000,
    "othercurrentreceivables": 71000,
    "currentprepaidexpenses": 56000,
    "currentprepayments": 2689000,
    "nameofassociate": "Associate: Stimunity S.A.",
    "principalplaceofbusinessofassociate": "Biotechnology",
    "countryofincorporationorresidenceofassociate": "Paris, France",
    "proportionofvotingpowerheldinassociate": 0.44,
    "unrecognisedshareoflossesofassociates": 260000,
    "unrecognisedimpairmentoflossesofassociates": -607000,
    "revenue": 100000,
    "equityinlossincome": 260000,
    "unrealizedgain": 39000,
    "increasingcarryingvalue": 653000,
    "impairmentanalysis": 607000,
    "stimunityconvertiblenotereceivable": 211000,
    "decreasingcarryingvalue": 806000,
    "stimunityconvertiblenote": 442000,
    "privateinvestments": 2087000,
    "unrealizedgainlossoninvestment": -5322000,
    "privateinvestmentsinterest": 4500000,
    "investmentownedshares": 1000000,
    "investmentownershippercentage": 0.075,
    "impairmentassetscarringvalue": 4046000,
    "reversestocksplitholdingshares": 644299,
    "interestreceivable": 2087000,
    "additionalrecognitiongoodwill": 1276000,
    "identifiableintangibleassetsrecognisedasofacquisitiondate": 28200000,
    "othertangibleorintangibleassetstransferred": 28738000,
    "acquisitiondatefairvalueoftotalconsiderationtransferred": 17200000,
    "identifiableassetsacquiredliabilitiesassumed": 3000000,
    "deferredtaxliabilitiesrecognisedasofacquisitiondate": 8538000,
    "contingentliabilitiesrecognisedinbusinesscombination": 28738000,
    "profitlossfromcontinuingoperations": -16277000,
    "earninglosspershare": -5.63,
    "numberofshareissued": 2425999,
    "ordinarysharesvalue": 18000000,
    "shorttermemployeebenefitsexpense": 2000000,
    "milestonepayment": 15000000,
    "deferredpurchasepricepayable": 8538000,
    "tarusgoodwill": 538000,
    "taxeffectofimpairmentofgoodwill": -43862000,
    "descriptionofdiscountratesappliedtocashflowprojections": 0.245,
    "aggregateimpairmentloss": 64723000,
    "impairmentlossonfinancialassets": 43862000,
    "deferredtaxesliability": 13195000,
    "recognizedimpairment": 59320000,
    "carryingvalue": 117210000,
    "impairment": 4585000,
    "deferredtaxliability": 10600000,
    "increaseindeferredincometaxes": 7000000,
    "increasedecreasethroughbusinesscombinationsdeferredtaxliabilityasset": 1100000,
    "reductionindeferredtaxliability": 17900000,
    "accruedbonusesandotherpayrollrelatedexpenses": 465000,
    "accruedlegalfees": 357000,
    "accountspayable": 274000,
    "accruedclinicalandrdservices": 264000,
    "accruedotherprofessionalfees": 229000,
    "accruedaccountingandauditingfees": 133000,
    "accruedcro": 58000,
    "accruedrentandadministration": 51000,
    "otheraccruedexpenses": 34000,
    "accountspayableandaccruedliabilitynet": 1865000,
    "currentfederalincometaxbenefit": -25000,
    "currenttaxexpenseincome": -25000,
    "deferredforeignincometaxbenefit": 17881000,
    "adjustmentsfordeferredtaxexpense": 17881000,
    "profitlossfromcontinuingoperation": -17856000,
    "lossonordinaryactivitiesbeforetax": -2252000,
    "statutoryu.s.incometaxrate": 0.21,
    "lossatstatutoryincometaxrate": 474000,
    "lossesunrecognized": -604000,
    "utilizationoflossesnotpreviouslybenefitted": 105000,
    "incometaxbenefitexpense": -25000,
    "accountingprofit": 63248000,
    "applicabletaxrate": 0.19,
    "taxexpenseincomeatapplicabletaxrate": 12017000,
    "changeincreaseindeferredincometaxrate": 3795000,
    "foreigncurrencyeffect": 2069000,
    "incometaxexpenses": 17881000,
    "pretaxloss": -2252000,
    "lossforwhichnobenefitwastaken": 2875000,
    "lossesnotsubjecttotax": 57022000,
    "utilizationoflossepreviouslybenefitted": -498000,
    "pretaxlosssubjecttotax": 125000,
    "deferredtaxassetsnetoperatinglosscarryforward": -4131000,
    "deferredtaxassetunrecognized": 1500000,
    "netdeferredtaxassets": -2631000,
    "deferredtaxliabilitiesinprocessrandd": 13195000,
    "deferredtaxliability1": 13195000,
    "netdeferredtaxliabilities": 10564000,
    "federalnetoperatinglosses": 700000,
    "deferredtaxassets": 200000,
    "researchanddevelopmentcreditreceivables": 200000,
    "researchanddevelopmentexpensecashcredits": 20000,
    "currentyearlosses": 700000,
    "fairvalueadjustmentshares": -33888,
    "fairvalueadjustment": -33000,
    "gainlossofchangeinfairvalueofwarrants": 33000,
    "commonstockshares": 17606000,
    "commonstockvalues": 218782000,
    "adjustedweightedaverageshares": 2426000,
    "acquisitionsthroughbusinesscombinationsotherprovisions": 17200000,
    "sharesissuedinioxexchangesshares": 1070000,
    "shareissuedinioxexchange": 9737000,
    "excessofnoncontrollinginterestacquiredoverconsiderationsiox": 29609000,
    "sharesissuedtolincolnparkcommittedpurchase": 900000,
    "sharesissuedunderpublicofferingandatmnetofissuecostshares": 167000,
    "sharesissuedunderpublicofferingandatmnetofissuecosts": 915000,
    "purchaseofsharesissuedundercommittedpurchaseagreementnetofissuecostsshares": 480000,
    "purchaseofsharesissuedundercommittedpurchaseagreementnetofissuecosts": 1977000,
    "increasedecreaseinnumberofordinarysharesissued": 20000,
    "saleorissueoftreasuryshares": 120000,
    "maximumaggregateofferingprice": 50000000000,
    "issuanceandsalesshares": 1150000000,
    "grossproceedsfromstock": 26500000,
    "sharesreceived": 363718,
    "numberofsharessold": 2425999,
    "numberofordinaryshareissued": 94508,
    "stockoptionreserve": 21204000,
    "settledinioxexchange": -11659000,
    "numberofoutstandingshareoption": 1963420000,
    "numberofshareoptionsgrantedinsharebasedpaymentsarrangement": 812020,
    "numberofshareoptionsexpiredorforfeitedinsharebasedpaymentsarrangement": -1275,
    "numberofshareoptionsexercisableinsharebasedpaymentsarrangements": 747163000,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 10.53,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P8Y10M9D",
    "stockgranted": 243000,
    "fairvaluepershare": 17.75,
    "communicationexpense": 4300000,
    "numberofoutstandingshareoptions": 7500,
    "weightedaverageshares": 16119000,
    "basicanddilutedlosspershare": -6.49,
    "costandexpenses": 12100000,
    "commitmentfee": 900000,
    "percentageownedonshares": 0.041,
    "portagepaidintensity": 69759000,
    "portageunpaidintensity": 63624000,
    "accruedinterest": 692045000,
    "principalpaidtodirector": 805000000,
    "exchangeofnotespayableforsalvarxwarrants": 2415000000,
    "warrantsprice": 6.64,
    "portageordinaryshares": 1070000,
    "annualfeesdescription": "Additionally, the chairperson of each of the Audit Committee, Compensation Committee and Nominating Committeeis entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members of those committees willbe entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.",
    "prepaidexpensesandotherreceivable": 2689000,
    "convertiblenotereceivableincludingaccruedinterestnetofimpairment": 442000,
    "currentinvestments": 806000,
    "investmentinprivatecompany": 2087000,
    "accountspayableandaccruedliabilities": 1865000,
    "notesreceivable": 614000,
    "unrealizedgains": 39000,
    "reversalofimpairmentloss": 211000,
    "decreasingimpairmentcarryingvalue": 442000,
    "gainondecreaseinfairvalueofliability": 1359000,
    "payablesandaccruedexpense": 1900000,
    "currentasset": 13700000,
    "shareholdersequityattributabletoowners": 76000000,
    "netlossattributabletononcontrollinginterest": 123000,
    "purchaseofnoncontrollinginterestpursuanttoshareexchangeagreement": -44824000,
    "interestintensityshares": 644229,
    "interestintensityvalue": 2087000,
    "additionalantidilutionshares": 2659
  },
  {
    "date": "2022-03-31",
    "symbol": "PRTG",
    "period": "FY",
    "documenttype": "20-F",
    "amendmentflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "documentperiodenddate": "2022-03-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2022,
    "currentfiscalyearenddate": "--03-31",
    "entityfilenumber": "0-30314",
    "entityregistrantname": "Portage Biotech Inc.",
    "entitycentralindexkey": 1095435,
    "entityincorporationstatecountrycode": "A6",
    "entityaddressaddressline1": "Clarence Thomas Building",
    "entityaddressaddressline2": "P.O. Box 4649",
    "entityaddressaddressline3": "Road Town",
    "entityaddresscityortown": "Tortola",
    "entityaddressstateorprovince": "CT",
    "entityaddresscountry": "VG",
    "entityaddresspostalzipcode": "VG1110",
    "cityareacode": 203,
    "localphonenumber": 221.7378,
    "security12btitle": "Ordinary Shares, no par value",
    "tradingsymbol": "PRTG",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "documentaccountingstandard": "International Financial Reporting Standards",
    "entityshellcompany": "false",
    "contactpersonnelname": "Ian Walters",
    "auditorfirmid": 688,
    "auditorname": "Marcum LLP",
    "auditorlocation": "Melville, NY",
    "cashandcashequivalents": 23352000,
    "tradeandothercurrentreceivables": 1480000,
    "currentassets": 24832000,
    "investmentsinsubsidiariesjointventuresandassociates": 1673000,
    "investmentproperty": 7409000,
    "goodwill": 43324000,
    "inprocessresearchanddevelopment": 117388000,
    "otherassets": 36000,
    "assets": 194662000,
    "tradeandothercurrentpayables": 750000,
    "warrantliabilitycurrent": 33000,
    "currentliabilities": 783000,
    "deferredtaxliabilities": 28445000,
    "noncurrentliabilities": 28445000,
    "liabilities": 29228000,
    "issuedcapital": 158324000,
    "otherreserves": 16928000,
    "accumulatedothercomprehensiveincome": 958000,
    "retainedearnings": -55005000,
    "equityattributabletoownersofparent": 121205000,
    "noncontrollinginterests": 44229000,
    "equity": 165434000,
    "equityandliabilities": 194662000,
    "researchanddevelopmentexpense": 6769000,
    "generalandadministrativeexpense": 8819000,
    "profitlossfromoperatingactivities": -15588000,
    "gainslossesonchangeinfairvalueofwarrants": 852000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -62000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 24000,
    "interestexpense": 43000,
    "profitlossbeforetax": -14817000,
    "incometaxexpensecontinuingoperations": 4352000,
    "profitloss": -19169000,
    "comprehensiveincome": -19169000,
    "profitlossattributabletoownersofparent": -16870000,
    "profitlossattributabletononcontrollinginterests": -2299000,
    "netloss": -19169000,
    "comprehensiveincomeattributabletoownersofparent": -16870000,
    "comprehensiveincomeattributabletononcontrollinginterests": -2299000,
    "basicanddilutedearningslosspershare": -1.29,
    "weightedaveragessharesoutstandingbasicanddiluted": 13060,
    "numberofsharesoutstanding": 13349,
    "shareissuerelatedcost": 1877000,
    "increasedecreasethroughsharebasedpaymenttransactions": 8951000,
    "sharesissuedunderatm": 2643000,
    "sharesissuedunderatmshares": 91,
    "sharesissuedunderoffering": 26450000,
    "sharesissuedunderofferingshares": 1150,
    "sharesissuedoraccruedforservices": 120000,
    "sharesissuedoraccruedforservicesshares": 8,
    "warrantsexercisedamount": 339000,
    "warrantsexercisedshares": 16,
    "exchangeofnotespayableandaccruedinterestforioxshares": 184000,
    "adjustmentsforsharebasedpayments": 9142000,
    "increasedecreaseindeferredtaxliabilityasset": 4394000,
    "lossincomeonfairvalueofwarrantliability": -852000,
    "fairvalueofstockissuedforservices": 120000,
    "gainlossonhedgeineffectiveness": 62000,
    "increasingdecreasingaccountsreceivable": 522000,
    "adjustmentsfordecreaseincreaseinprepaidexpenses": 355000,
    "adjustmentsfordecreaseincreaseinotherassets": -165000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": -1212000,
    "adjustmentsforincreasedecreaseinotherliabilities": 39000,
    "cashflowsfromusedinoperatingactivities": -6764000,
    "proceedsfromsharesissuedunderregisteredoffering": 29093000,
    "paymentsforshareissuecosts": 1852000,
    "proceedsfromexerciseofwarrants": 105000,
    "cashflowsfromusedinfinancingactivities": 27346000,
    "increasedecreaseincashandcashequivalents": 20582000,
    "cashpaidforinterest": 19000,
    "increaseinaccountspayableforstockissuancecosts": 25000,
    "decreaseinwarrantliabilityfromwarrantexercise": 235000,
    "exchangeofioxsharesforsettlementofnotespayableaccruedinterestandwarrants": 184000,
    "percentageofvotingequityinterestsacquired": 0.0735,
    "issuanceandsales": 200000000,
    "maximumaggregateofferingprice": 50000000,
    "cash": 23400000,
    "totalcurrentliabilities": 800000,
    "warrantliability": 30000,
    "netlossincome": 19200000,
    "cashusedinoperatingactivities": 6800000,
    "cashonhand": 21000000,
    "antidilutiveeffectonlosspershare": 1151400,
    "currentadvancestosuppliers": 1084000,
    "researchanddevelopmentcredit": 169000,
    "taxdeposits": 142000,
    "currentprepaidexpenses": 45000,
    "othercurrentreceivables": 40000,
    "currentprepayments": 1480000,
    "proportionofownershipinterestinsubsidiary": 0.7,
    "proportionofownershipinterestsheldbynoncontrollinginterests": 0.3,
    "loanspayableindefault": 11250,
    "prepaidexpensesandotherreceivables": 33750,
    "prepaidexpensesandotherreceivablescurrent": 11250,
    "prepaidexpensesandotherreceivablesnoncurrent": 22500,
    "nameofassociate": "Associate:    Stimunity S.A.",
    "principalplaceofbusinessofassociate": "Biotechnology",
    "countryofincorporationorresidenceofassociate": "Paris,    France",
    "proportionofvotingpowerheldinassociate": 0.44,
    "unrecognisedshareoflossesofassociates": 62000,
    "revenue": 200000,
    "equityinlossincome": 62000,
    "privateinvestments": 7409000,
    "investmentownedshares": 1000000,
    "investmentownershippercentage": 0.075,
    "descriptionofdiscountratesappliedtocashflowprojections": 0.205,
    "deferredtaxesliability": 30198000,
    "deferredtaxliability": 30200000,
    "taxeffectofranddcredit": 42000,
    "increasedecreasethroughbusinesscombinationsdeferredtaxliabilityasset": 1100000,
    "accountspayable": 188000,
    "accruedbonuses": 193000,
    "accruedlegalfees": 186000,
    "accruedotherprofessionalfees": 75000,
    "accruedaccountingandauditingfees": 69000,
    "otheraccruedexpenses": 39000,
    "accountspayableandaccruedliabilitynet": 750000,
    "exchangeofnotespayableandaccruedinterestforioxshare": -150000,
    "issuanceofunsecurednotesdescription": "Theholders of the SalvaRx Notes received $7,500 of warrants in respect of each $10 thousand of principal issued. The warrants vest in theevent of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx. On the Acquisition Date,the fair value of the warrants, which are included in non-controlling interest, was determined to be $2.5 million using the Black-Scholesmodel.",
    "sharesreceived": 363718,
    "currentforeignincometaxbenefit": 42000,
    "currenttaxexpenseincome": 42000,
    "deferredforeignincometaxbenefit": -4394000,
    "adjustmentsfordeferredtaxexpense": -4394000,
    "lossonordinaryactivitiesbeforetax": 1342000,
    "statutoryu.s.incometaxrate": 0.21,
    "lossatstatutoryincometaxrate": 282000,
    "lossesunrecognized": 282000,
    "accountingprofit": 4127000,
    "applicabletaxrate": 0.19,
    "taxexpenseincomeatapplicabletaxrate": 784000,
    "changeincreaseindeferredincometaxrate": -6998000,
    "recognitionofdeferredtaxassets": 722000,
    "foreigncurrencyeffect": 1098000,
    "taxeffectoftaxlosses": 13000000,
    "incometaxexpenses": -4352000,
    "pretaxloss": -1342000,
    "lossesnotsubjecttotax": 9348000,
    "pretaxlosssubjecttotax": -1342000,
    "deferredtaxassetsnetoperatinglosscarryforward": -3253000,
    "deferredtaxassetunrecognized": 1500000,
    "netdeferredtaxassets": -1753000,
    "deferredtaxliabilitiesinprocessrandd": 30198000,
    "deferredtaxliability1": 30198000,
    "netdeferredtaxliabilities": 28445000,
    "researchanddevelopmentcreditreceivables": 200000,
    "researchanddevelopmentexpensecashcredits": 40000,
    "warrantsoutstandingexerciseprice": 6.64,
    "warrantsoutstandingshares": 33888,
    "warrantsoutstandingamount": 33000,
    "exerciseofwarrantsexerciseprice": 6.64,
    "exerciseofwarrantsshares": -15813,
    "exerciseofwarrantsamount": -235000,
    "fairvalueadjustment": -852000,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0106,
    "optionlifeshareoptionsgranted": "P0Y6M10D",
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.5149,
    "gainlossofchangeinfairvalueofwarrants": 900000,
    "commonstockshares": 13349000,
    "commonstockvalues": 158324000,
    "sharesissuedinpublicofferingandatmshares": 1241000,
    "sharesissuedinpublicofferingandatm": 27216000,
    "warrantsexercisedshares1": 16000,
    "sharesissuedforservicesshares1": 8000,
    "sharesissuedforservice": 120000,
    "stockoptionreserve": 11659000,
    "numberofoutstandingshareoption": 1151400,
    "numberofshareoptionsgrantedinsharebasedpaymentsarrangement": 343400,
    "numberofshareoptionsexpiredorforfeitedinsharebasedpaymentsarrangement": -60000,
    "numberofshareoptionsexercisableinsharebasedpaymentsarrangements": 405997,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 15.47,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P9Y1M6D",
    "stockoptionsissued": 2980,
    "stockgranted": 243000,
    "fairvaluepershare": 17.75,
    "communicationexpense": 4300000,
    "weightedaverageshares": 13060000,
    "basicanddilutedlosspershare": -1.29,
    "prepaidexpensesandotherreceivable": 1480000,
    "currentinvestments": 9082000,
    "accountspayableandaccruedliabilities": 750000,
    "portagepaidintensity": 83437,
    "annualfeesdescription": "Additionally, the chairpersonof each of the Audit Committee, Compensation Committee and Nomination Committee will be entitled to annual fees of $15,000, $12,000 and$8,000, respectively, payable quarterly in arrears. Members of those committees will be entitled to annual fees of $7,500, $6,000 and$4,000, respectively, payable quarterly in arrears.",
    "payablesandaccruedexpense": 800000,
    "currentasset": 24800000,
    "shareholdersequityattributabletoowners": 121200000,
    "stockbasedcompensationexpense": 191000,
    "exchangeofnotespayableaccruedinterestandwarrantsforioxshares": 184000,
    "netlossattributabletononcontrollinginterest": -1847000
  },
  {
    "date": "2021-03-31",
    "symbol": "PRTG",
    "period": "FY",
    "entityregistrantname": "Portage Biotech Inc.",
    "entitycentralindexkey": 1095435,
    "documenttype": "20-F",
    "documentperiodenddate": "2021-03-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--03-31",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entityfilercategory": "Non-accelerated Filer",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2021,
    "entityincorporationstatecountrycode": "A6",
    "entityinteractivedatacurrent": "Yes",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "cash": 2770000,
    "tradeandothercurrentreceivables": 11250,
    "currentassets": 1600000,
    "otherreceivables": 22000,
    "investmentsinsubsidiariesjointventuresandassociates": 1735000,
    "investmentproperty": 7409000,
    "goodwill": -24050000,
    "inprocessresearchanddevelopment": 178000,
    "otherassets": 36000,
    "assets": 174860000,
    "tradeandothercurrentpayables": 1938000,
    "warrantliabilitycurrent": 1120000,
    "unsecurednotespayable": 150000,
    "currentliabilities": 700000,
    "noncurrentpayables": 150000,
    "deferredtaxliabilities": 24050000,
    "noncurrentliabilities": 100000,
    "liabilities": 27258000,
    "issuedcapital": 130649000,
    "otherreserves": 7977000,
    "accumulatedothercomprehensiveincome": 958000,
    "retainedearnings": -38135000,
    "equityattributabletoownersofparent": 400000,
    "noncontrollinginterests": -20000,
    "equity": 800000,
    "equityandliabilities": 174860000,
    "researchanddevelopmentexpense": 7312000,
    "generalandadministrativeexpense": 5128000,
    "profitlossfromoperatingactivities": -1500000,
    "gainonsaleofmarketableequitysecurities": -72000,
    "gainslossesonchangeinfairvalueofwarrants": -790000,
    "lossonequityissuedatdiscount": 1256000,
    "lossesgainsonextinguishmentofdebt": -223000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -490000,
    "gainslossesondisposalsofinvestments": 412000,
    "interestexpense": 177000,
    "profitlossbeforetax": -14892000,
    "incometaxexpensecontinuingoperations": 2297000,
    "profitloss": -1100000,
    "comprehensiveincome": -17189000,
    "profitlossattributabletoownersofparent": -15833000,
    "profitlossattributabletononcontrollinginterests": -1356000,
    "comprehensiveincomeattributabletoownersofparent": -15833000,
    "comprehensiveincomeattributabletononcontrollinginterests": -1356000,
    "basicanddilutedearningslosspershare": -1.35,
    "weightedaveragessharesoutstandingbasicanddiluted": 11733,
    "numberofsharesoutstanding": 12084,
    "issuedunderprivateplacement": 6980000,
    "issuedunderprivateplacementshares": 698,
    "paymentsforshareissuecosts": -248000,
    "exchangeofsalvarxwarrantsforportagewarrants": 2640000,
    "settlementofnoncontrollinginterestinsalvarxlimited": 2451000,
    "warrantliabilityatcontractprice": -330000,
    "fairvalueadjustmentforsharesissuedatdiscountinsalvarxlimited": 1256000,
    "fairvalueadjustmentforsharesissuedatdiscountinsalvarxlimitedshares": 397,
    "sharesissuedforservices": 25000,
    "sharesissuedforservicesshares": 1,
    "expirationofunexercisedstockoptions": 58000,
    "increasedecreasethroughsharebasedpaymenttransactions": 7977000,
    "increasedecreaseindeferredtaxliabilityasset": 2446000,
    "netforeignexchangeloss": 5160000,
    "lossincomeonfairvalueofwarrantliability": 790000,
    "adjustmentsforamortisationexpense": 76000,
    "adjustmentsforlossonextinguishmentofunsecurednotes": 223000,
    "gainlossonhedgeineffectiveness": 490000,
    "adjustmentsforsharebasedpayments": 7977000,
    "fairvalueofstockissuedforservices": 25000,
    "gainondispositionofsubsidiaries": -412000,
    "increasingdecreasingaccountsreceivable": -111000,
    "adjustmentsfordecreaseincreaseinotherassets": -1477000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 880000,
    "otherasset": -36000,
    "cashflowsfromusedinoperatingactivities": -4284000,
    "proceedsfromsalesofinvestmentproperty": 140000,
    "purchaseofinvestmentproperty": 1000000,
    "cashflowsfromusedininvestingactivities": -860000,
    "proceedsfromsharesissuedunderprivateplacement": 6980000,
    "repaymentofunsecurednotespayable": -1020000,
    "repaymentofadvancefromrelatedparty": -1000000,
    "noteproceedsreceived": -50000,
    "cashflowsfromusedinfinancingactivities": 4762000,
    "increasedecreaseincashandcashequivalents": -382000,
    "cashandcashequivalents": 2770000,
    "cashpaidforinterest": 748000,
    "sharesissuedpursuanttosettlementofsalvarxnotesandwarrants": 2640000,
    "fairvalueofwarrantliabilityforportagewarrantsissued": 1120000,
    "notespayablesettledindispositionofsubsidiaries": 200000,
    "percentageofvotingequityinterestsacquired": 0.08,
    "maximumaggregateofferingprice": 50000000,
    "issuanceandsales": 200000000,
    "warrantliability": 1120000,
    "proportionofownershipinterestinsubsidiary": 0.3951,
    "proportionofownershipinterestsheldbynoncontrollinginterests": 0.3,
    "antidilutiveeffectonlosspershar": 49701,
    "currentadvancestosuppliers": 1445000,
    "researchanddevelopmentcredit": 649000,
    "currentprepaidexpenses": 48000,
    "othercurrentreceivables": 34000,
    "currentprepayments": 2176000,
    "tradeandotherreceivables": 86250,
    "loanspayableindefault": 11250,
    "currentportionoflongtermborrowings": 33750,
    "prepaidexpensesandotherreceivables": 2176000,
    "gainonsale": 72000,
    "nameofassociate": "Associate:Stimunity S.A.",
    "principalplaceofbusinessofassociate": "Biotechnology",
    "countryofincorporationorresidenceofassociate": "Paris, France",
    "proportionofvotingpowerheldinassociate": 0.44,
    "additionalinvestments": 1000000,
    "unrecognisedshareoflossesofassociates": -490000,
    "revenue": 100000,
    "equityinlossincome": -490000,
    "privateinvestments": 4500000,
    "unrealizedgainlossoninvestment": 700000,
    "investmentownedshares": 1000000,
    "investmentownershippercentage": 0.075,
    "netlossapplicabletocommonstockholders": 3920000,
    "netlosspersharebasicanddiluted": -0.01,
    "foreignexchangeeffectondeferredliabilitysettleableingreatbritishpounds": -2446000,
    "descriptionofdiscountratesappliedtocashflowprojections": 0.2,
    "increasedecreasethroughbusinesscombinationsdeferredtaxliabilityasset": 2400000,
    "accountspayable": 113000,
    "insurancepremiumnote": 1651000,
    "accruedinterest": 5000,
    "otheraccruedexpenses": 169000,
    "accountspayableandaccruedliabilitynet": 1938000,
    "notepayable": 150000,
    "repaymentofnotespayable": -1020000,
    "amortizationofdebtdiscount": 76000,
    "valueofnotesexchangedinwarrantexercise": -2640000,
    "settlementinconnectionwithdispositionofppl": -200000,
    "lossonextinguishmentofdebt": 223000,
    "proceedsfromloanpayable": 50000,
    "aggregateprincipalamountofunsecurednotes": 200000,
    "unsecurednotesinterest": 0.07,
    "issuanceofunsecurednotesdescription": "The holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10 thousand of principal issued. The warrants vest in the event of a qualifying transaction and are exercisable at a 30% discount to the implied valuation of SalvaRx. On the Acquisition Date, the fair value of the warrants, which are included in non-controlling interest, was determined to be $2.5 million using the Black Scholes Model.",
    "financialliabilitiesatfairvalue": 24000000,
    "sharesreceived": 363718,
    "warrantsoutstandingexerciseprice": 6.64,
    "exchangeofwarrantspursuanttosalvarxnotessettlementexerciseprice": 6.64,
    "reclassificationtoaccruedequityissuablemexerciseprice": 6.64,
    "warrantsoutstandingshares": 49701,
    "exchangeofwarrantspursuanttosalvarxnotessettlementshares": -447305,
    "reclassificationtoaccruedequityissuableshares": -397604,
    "warrantsoutstandingamount": 1120000,
    "exchangeofwarrantspursuanttosalvarxnotessettlementamount": -2970000,
    "reclassificationtoaccruedequityissuableamount": -2640000,
    "fairvalueadjustment": 790000,
    "commonstockvalues": 12084000,
    "commonstockshares": 130649000,
    "sharesissuedinprivateplacementnetofissuecosts": 698000,
    "sharesissuedinprivateplacementnetofissuecostsshares": 6732000,
    "exchangeofsalvarxwarrantsforpbiwarrantsshares": 2640000,
    "settlementofnoncontrollinginterestinsalvarxshares": 2451000,
    "toreflectwarrantsissuedandoutstandingshares": -330000,
    "fairvalueadjustmentforsharesissuedatdiscountinsalvarx": 397000,
    "fairvalueadjustmentforsharesissuedatdiscountinsalvarxshares": 1256000,
    "expirationofunexercisedstockoptionsshares": 58000,
    "sharesissuedforservice": 1000,
    "offeringexpenses": 250000,
    "stockoptionreserve": 11468000,
    "stockissuedvaluestockoptionsexercised": 58000,
    "dateofgrantofsharebasedpaymentarrangement": "November 28, 2016",
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0048,
    "descriptionofexpectedvolatilityshareoptionsgranted": 1.39,
    "optionlifeshareoptionsgranted": "P5Y6M",
    "fairvalueatmeasurementdatesharesoptionsgranted": 16.66,
    "numberofoutstandingshareoption": 1924,
    "numberofshareoptionsgrantedinsharebasedpaymentsarrangement": 868000,
    "numberofshareoptionsexpiredorforfeitedinsharebasedpaymentsarrangement": -675,
    "numberofshareoptionsexercisableinsharebasedpaymentsarrangements": 1604,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 15,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P1Y8M19D",
    "fairvalueofvestedioxoptionsacquired": 7400000000,
    "stockoptionsissued": 2980,
    "communicationexpense": 4300000,
    "stockgranted": 243000,
    "fairvaluepershare": 17.75,
    "accountingprofit": 1218000,
    "applicabletaxrate": 0.19,
    "taxexpenseincomeatapplicabletaxrate": 231000,
    "foreigncurrencyeffectondeferredtaxliability": -2542000,
    "otheradjustments": 96000,
    "taxeffectofranddcredit": 149000,
    "taxeffectoftaxlosses": 7300000,
    "pretaxloss": -1218000,
    "lossesnotsubjecttotax": 13674000,
    "taxableloss": -1218000,
    "deferredtaxassetsnetoperatinglosscarryforward": 1417000,
    "netdeferredtaxassets": 1417000,
    "deferredtaxliabilitiesinprocessrandd": 24050000,
    "netdeferredtaxliabilities": 24050000,
    "researchanddevelopmentrefundablecredits": 100000,
    "researchanddevelopmentcreditreceivables": 649000,
    "taxrateeffectoftaxlosses": 0.19,
    "researchanddevelopmentexpensecashcredits": 1000000,
    "weightedaverageshares": 11733,
    "basicanddilutedlosspershare": -1.35,
    "commitmenttoinvestment": 1900000,
    "discretionaryinvestment": 688359,
    "additionaldiscretionaryinvestment": 1000000,
    "interestcostsincurred": 78427,
    "principalpaidtodirector": 805000,
    "exchangeofnotespayableforsalvarxwarrants": 2415000,
    "warrantsprice": 6.64,
    "currentinvestments": 9144000,
    "accountspayableandaccruedliabilities": 1938000,
    "fairvaluemarketpricepershare": 34.03,
    "payablesandaccruedexpense": 1900000,
    "stockbasedcompensationexpense": 850000,
    "exchangeofsalvarxwarrantsforpbiwarrantsinsalvarxnotessettlement": -2451000,
    "netlossattributabletononcontrollinginterest": -48000
  },
  {
    "date": "2020-03-31",
    "symbol": "PRTG",
    "period": "FY",
    "entityregistrantname": "Portage Biotech Inc.",
    "entitycentralindexkey": 1095435,
    "documenttype": "20-F",
    "documentperiodenddate": "2020-03-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--03-31",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "No",
    "entityvoluntaryfilers": "No",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entityfilercategory": "Non-accelerated Filer",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2020,
    "entityincorporationstatecountrycode": "A6",
    "entityinteractivedatacurrent": "No",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "cash": 3152000,
    "tradeandothercurrentreceivables": 11250000,
    "investmentassetavailableforsale": 68000,
    "currentassets": 1300000,
    "otherreceivables": 34000,
    "investmentsinsubsidiariesjointventuresandassociates": 1225000,
    "investmentproperty": 7409000,
    "goodwill": 43324000,
    "inprocessresearchanddevelopment": 178000,
    "assets": 173174000,
    "tradeandothercurrentpayables": 1268000,
    "unsecurednotespayable": 300000,
    "amountspayablerelatedpartytransactions": 1000000,
    "currentliabilities": 300000,
    "noncurrentpayables": 3661000,
    "deferredtaxliabilities": 21600000,
    "noncurrentliabilities": 100000,
    "liabilities": 27533000,
    "issuedcapital": 117817000,
    "otherreserves": 58000,
    "accumulatedothercomprehensiveincome": 958000,
    "retainedearnings": -22302000,
    "equityattributabletoownersofparent": 300000,
    "noncontrollinginterests": 28000,
    "equity": 900000,
    "equityandliabilities": 173174000,
    "researchanddevelopmentexpense": 4108000,
    "generalandadministrativeexpense": 1870000,
    "profitlossfromoperatingactivities": -300000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": 18000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 1431000,
    "lossesgainsonextinguishmentofdebt": -33000,
    "gainslossesonchangeinfairvalueofwarrants": 24000,
    "revenuefrominterest": 11000,
    "interestexpense": 557000,
    "profitlossbeforetax": -5084000,
    "incometaxexpensecontinuingoperations": 2165000,
    "profitloss": -1916000,
    "gainsondisposalsofinvestmentproperties": 876000,
    "comprehensiveincome": -6373000,
    "profitlossattributabletoownersofparent": -5333000,
    "profitlossattributabletononcontrollinginterests": -1916000,
    "comprehensiveincomeattributabletoownersofparent": -4457000,
    "comprehensiveincomeattributabletononcontrollinginterests": -1916000,
    "basicearningslosspershare": -0.49,
    "dilutedearningslosspershare": -0.49,
    "weightedaveragesharesoutstandingbasic": 10951531,
    "weightedaveragesharesoutstandingdiluted": 10951531,
    "numberofsharesoutstanding": 1098770596,
    "stockissuedvaluestockoptionsexercised": 282000,
    "unrealizedgainoninvestmentavailableforsale": 876000,
    "stockissuedduringperiodsharesofacquisition": 129806,
    "stockissuedduringperiodvalueofacquisitiontwo": 1298000,
    "expirationofunexercisedstockoptions": 282000,
    "increasedecreasethroughsharebasedpaymenttransactions": 2159000,
    "adjustmentsforsharebasedpayments": 16000,
    "adjustmentsforsharebasedcompensationexpensedasresearchanddevelopment": 16000,
    "adjustmentsforamortisationexpense": 265000,
    "adjustmentsforlossonextinguishmentofunsecurednotes": 33000,
    "netforeignexchangeloss": 5160000,
    "subsidiarysexpensestodateofdeconsolidation": -18000,
    "adjustmentsforgainslossesonchangeinfairvalueofwarrants": -24000,
    "adjustmentsfordecreaseincreaseinotherassets": -281000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 167000,
    "cashflowsfromusedinoperatingactivities": -3714000,
    "cashadvancesandloansfromrelatedparties": 1000000,
    "proceedsfromissuanceandrepaymentofnotespayable": 300000,
    "cashflowsfromusedinfinancingactivities": 700000,
    "increasedecreaseincashandcashequivalents": -3014000,
    "cashandcashequivalents": 3152000,
    "fairvalueofsharesissuedtoacquireintensityholdingslimited": 1298000,
    "unrealizedgainlossoninvestmentinbiohaven": 876000,
    "percentageofvotingequityinterestsacquired": 0.09,
    "workingcapital": 700000,
    "cashfunddescription": "The &#160;&#160;Company's current cash along with the $6.7 million net cash proceeds raised from the equity financing during June 2020 will be sufficient to fund operations for at least the next 12 months through August 2021.&#160;",
    "proportionofownershipinterestinsubsidiary": 0.3951,
    "proportionofownershipinterestsheldbynoncontrollinginterests": 0.3,
    "currentprepaidexpenses": 14000,
    "researchanddevelopmentcredit": 500000,
    "othercurrentreceivables": 60000,
    "currentprepayments": 574000,
    "tradeandotherreceivables": 75000000,
    "loanspayableindefault": 11250000,
    "currentportionoflongtermborrowings": 33750000,
    "lossesondisposalsofinvestmentproperties": -35000,
    "fairvaluesharesinvestment": 2000,
    "fairvalueamount": 68060,
    "parvaluepershare": 34.03,
    "unrealizedgains": 34880,
    "unrecognisedshareoflossesofassociates": 18000,
    "nameofassociate": "Associate:Stimunity S.A.",
    "principalplaceofbusinessofassociate": "Biotechnology",
    "countryofincorporationorresidenceofassociate": "Paris, France",
    "proportionofvotingpowerheldinassociate": 0.364,
    "revenue": 200000,
    "descriptionofamountsofassetsliabilitiesequityinterestsoritemsofconsiderationforwhichinitialaccountingisincomplete": "PPL is also committed to providing a contribution of &#xa3;33,419 ($45,486) payable in three annual instalments for tuition expenses with the University of Glasgow (see note 17). The Company paid $15,606 and $29,880, during the years ended March 31, 2018 and March 31, 2020, respectively.&#160;",
    "privateinvestments": 4500000,
    "paymentforacquisition": 1298000,
    "unrealizedgainlossoninvestment": 911000,
    "investmentownedshares": 1000000,
    "investmentownershippercentage": 0.075,
    "netlossapplicabletocommonstockholders": 3920000,
    "basicanddilutedearningslosspershare": -0.01,
    "profitlossofacquiree": 2900000,
    "fairvalueofwarrants": 2500000,
    "fairvalueofvestedportion": 7400000,
    "accountspayable": 343000,
    "accruedinterest": 701000,
    "otheraccruedexpenses": 224000,
    "accountspayableandaccruedliabilitynet": 1268000,
    "fairvalueofstock": 1354.88,
    "riskfreeinterestrate": 0.01,
    "expectedvolatility": 0.8,
    "expectedlife": "P2Y7M6D",
    "notepayable": 3661000,
    "repaymentofnotespayable": -300000,
    "interestofnotespayable": 265000,
    "lossonextinguishmentofdebt": 33000,
    "fairvalueonacquisition": -24000,
    "aggregateprincipalamountofunsecurednotes": 200000,
    "unsecurednotesinterest": 0.07,
    "issuanceofunsecurednotesdescription": "In conjunction with the issuance of the Unsecured Notes, the note holders were also issued a warrant to subscribe for $7,500 new PPL or Eygen ordinary shares for every $10,000 of principal issued, respectively, provided that a certain qualifying event occurs within the three years of issuance.",
    "financialliabilitiesatfairvalue": 24000000,
    "commonstockvalues": 117817000,
    "commonstockshares": 10987706,
    "sharesissuedonacquisitionofintensityholdinglimited": 1298000,
    "sharesissuedonacquisitionofintensityholdinglimitedshares": 129806,
    "increasedecreaseinnumberofsharesoutstanding": 10987706,
    "stockoptionreserve": 58000,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.026,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.8,
    "optionlifeshareoptionsgranted": "P3Y2M12D",
    "fairvalueofstocks": 6.27,
    "fairvalueatmeasurementdatesharesoptionsgranted": 4630.35,
    "numberofoutstandingshareoption": 2599,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 47917,
    "numberofshareoptionsexercisableinsharebasedpaymentsarrangements": 1643,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 148.84,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P1Y7M17D",
    "stockoptionsissued": 2980,
    "descriptionofmaximumtermofoptionsgrantedforsharebasedpaymentarrangement": "The stock options vest quarterly over 4 years and expire in five years.",
    "expecteddividendshareoptionsgranted": 40000,
    "communicationexpense": 2200000,
    "sharesissueddescription": "were issued under 2011 Consultant Stock Compensation Plan to six consultants. including 13,900 to five directors, for services provided.",
    "accountingprofit": 2409000,
    "applicabletaxrate": 0.19,
    "taxexpenseincomeatapplicabletaxrate": 458000,
    "changeindeferredrateandtrueup": 2665000,
    "taxeffectofranddcredit": -500000,
    "taxeffectoftaxlosses": 5100000,
    "deferredtaxassetsnetoperatinglosscarryforward": 1528000,
    "netdeferredtaxassets": 1528000,
    "deferredtaxliabilitiesinprocessrandd": 21604000,
    "netdeferredtaxliabilities": 21604000,
    "taxrateeffectoftaxlosses": 0.19,
    "researchanddevelopmentexpensecashcredits": 466000,
    "deferredtaxexpenseincome": 2200000,
    "increasedecreaseindeferredtaxliabilityasset": 2300000,
    "deferredtaxexpensesreturntoprovisionadjustment": 400000,
    "antidilutiveeffectstockoptionsincomputationofdilutedloss": 2980,
    "commitmenttoinvestment": 1500000,
    "additionaldiscretionaryinvestment": 600129000,
    "obligationtomakecapitalcontribution": 300000,
    "prepaidexpensesandotherreceivables": 74000,
    "currentinvestments": 7477000,
    "accountspayableandaccruedliabilities": 1268000,
    "fairvaluemarketpricepershare": 34.03,
    "payablesandaccruedexpense": 1300000,
    "cashinhand": 3200000,
    "stockbasedcompensationexpense": 2143000,
    "netlossattributabletononcontrollinginterest": -1916000,
    "inprocessresearchanddevelopmentgross": 88459000,
    "changesininprocessresearchanddevelopment": 28929000,
    "percentageofvalueassigned": 0.7,
    "descriptionofdiscountratesappliedtocashflowprojections": 0.205,
    "amountusedformaterialsinlabs": 200000,
    "notesanddebenturesissued": 3200000,
    "initialinvestment": 600000,
    "additionalinvestment": 300000,
    "managementfees": 50000,
    "scientistfees": 50000
  },
  {
    "date": "2019-03-31",
    "symbol": "PRTG",
    "period": "FY",
    "entityregistrantname": "PORTAGE BIOTECH INC.",
    "entitycentralindexkey": 1095435,
    "documenttype": "20-F",
    "documentperiodenddate": "2019-03-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--03-31",
    "entitywellknownseasonedissuer": "No",
    "entitycurrentreportingstatus": "No",
    "entityvoluntaryfilers": "No",
    "entityextransitionperiod": "false",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "entityfilercategory": "Non-accelerated Filer",
    "entitycommonstocksharesoutstanding": 1085789986,
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2019,
    "entityincorporationstatecountrycode": "A6",
    "entityinteractivedatacurrent": "No",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "cash": 6166000,
    "tradeandothercurrentreceivables": 282000,
    "investmentassetavailableforsale": 103000,
    "currentassets": 700000,
    "otherreceivables": 45000,
    "investmentsinsubsidiariesjointventuresandassociates": 1207000,
    "investmentproperty": 5200000,
    "goodwill": 43324000,
    "inprocessresearchanddevelopment": 117388000,
    "assets": 173715000,
    "tradeandothercurrentpayables": 1107000,
    "unsecurednotespayable": 3663000,
    "warrantliabilitycurrent": 24000,
    "currentliabilities": 100000,
    "noncurrentpayables": 3000000,
    "deferredtaxliabilities": 20364000,
    "noncurrentliabilities": 23364000,
    "liabilities": 25158000,
    "issuedcapital": 116237000,
    "otherreserves": 324000,
    "accumulatedothercomprehensiveincome": 82000,
    "retainedearnings": -16969000,
    "equityattributabletoownersofparent": 200000,
    "noncontrollinginterests": 87000,
    "equity": 324000,
    "equityandliabilities": 173715000,
    "researchanddevelopmentexpense": 762000,
    "servicesexpense": 390000,
    "professionalfeesexpense": 247000,
    "operatingexpense": 134000,
    "profitlossfromoperatingactivities": -500000,
    "shareofprofitlossofassociatesaccountedforusingequitymethod": -162000,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": -691000,
    "revenuefrominterest": 111000,
    "interestexpense": 88000,
    "profitloss": -2635000,
    "gainsondisposalsofinvestmentproperties": 50000,
    "comprehensiveincome": -3544000,
    "profitlossattributabletoownersofparent": -2217000,
    "profitlossattributabletononcontrollinginterests": -959000,
    "comprehensiveincomeattributabletoownersofparent": -2585000,
    "comprehensiveincomeattributabletononcontrollinginterests": -959000,
    "weightedaveragesharesoutstandingbasic": 481987,
    "weightedaveragesharesoutstandingdiluted": 481987,
    "numberofsharesoutstanding": 1085790,
    "adjustmentsforsharebasedpayments": 57000,
    "unrealizedgainoninvestmentavailableforsale": 50000,
    "stockissuedduringperiodvalueofacquisition": 92583000,
    "stockissuedduringperiodsharesofacquisition": 805070000,
    "fairvalueofacquiredsubsidiariesattributabletononcontrollinginterestonacquisition": 48731000,
    "adjustmentsforsharebasedcompensationexpensedasresearchanddevelopment": 20000,
    "adjustmentsfordecreaseincreaseinotherassets": 352000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 363000,
    "cashflowsfromusedinoperatingactivities": -858000,
    "proceedsfromsaleofsalvarxacquisition": 1192000,
    "purchaseofinvestmentproperty": 688000,
    "purchaseofnotesreceivableissuedbysalvarxltd.priortoacquisitionbyportage": 950000,
    "cashflowsfromusedininvestingactivities": -446000,
    "proceedsfromissuanceandrepaymentofnotespayable": 50000,
    "cashflowsfromusedinfinancingactivities": -50000,
    "increasedecreaseincashandcashequivalents": -1354000,
    "cashandcashequivalents": 6166000,
    "fairvalueofsharesissuedtoacquiresalvarxltd.": 92583000,
    "unrealizedgainlossoninvestmentinbiohaven": 50000,
    "effectivesettlementofconvertiblenotesissuedbysalvarxltd.uponacquisitionbyportage": 1963000,
    "workingcapital": 4800000,
    "cashfunddescription": "The Company’s current cash is sufficient to fund operations for at least the next 12 months because the Company extended the maturity date of $3.4 million of principal and interest on the SalvaRx Notes to 2021 and can defer discretionary research and development and cash compensation by approximately $1.4 million.",
    "proportionofownershipinterestinsubsidiary": 0.3951,
    "currentprepaidexpenses": 19000,
    "researchanddevelopmentcredit": 208000,
    "othercurrentreceivables": 55000,
    "currentprepayments": 282000,
    "tradeandotherreceivables": 63750,
    "loanspayableindefault": 11250,
    "currentportionoflongtermborrowings": 45000,
    "descriptionofriskfreediscountrateshareoptionsgranted": 0.03,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.026,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.8,
    "issueofconvertibleinstruments": 2000000,
    "sharesissuedpricepershare1": 120,
    "conversionpricediscounted": 0.25,
    "planassetsatfairvalue": 2000000,
    "fairvaluesharesinvestment": 2000,
    "fairvalueamount": 102940,
    "parvaluepershare": 51.47,
    "unrealizedgains": 50420,
    "additionalinvestments": 688000,
    "unrecognisedshareoflossesofassociates": -162000,
    "nameofassociate": "Stimunity S.A.",
    "principalplaceofbusinessofassociate": "Biotechnology",
    "countryofincorporationorresidenceofassociate": "Paris, France",
    "proportionofvotingpowerheldinassociate": 0.365,
    "revenue": 200000,
    "descriptionofamountsofassetsliabilitiesequityinterestsoritemsofconsiderationforwhichinitialaccountingisincomplete": "PPL is also committed to providing a contribution of £33,419 ($46,837) payable in instalments of £11,140 ($15,606) per year for tuition expenses with the University of Glasgow (see note 17). One instalment of $15,606 was made in 2018. The 2019 installment of $15,606 has been accrued but not paid.",
    "privateinvestments": 700000000,
    "investmentownershippercentage": 0.0506,
    "investmentownedshares": 210210,
    "netforeignexchangeloss": -5160000,
    "netlossapplicabletocommonstockholders": -3920000,
    "basicanddilutedearningslosspershare": -0.01,
    "acquisitioncostincurred": 100000,
    "fairvalueofwarrants": 2500000,
    "fairvalueofvestedportion": 7400000,
    "accountspayable": 388,
    "accruedinterest": 523,
    "otheraccruedexpenses": 196,
    "accountspayableandaccruedliabilitynet": 1107,
    "fairvalueofstock": 1355,
    "riskfreeinterestrate": 0.01,
    "expectedvolatility": 0.8,
    "expectedlife": "P2Y7M6D",
    "notepayable": 3370000,
    "repaymentofnotespayable": -25000,
    "interestofnotespayable": 2000,
    "fairvalueonacquisition": 100000,
    "warrantliabilities": 2000,
    "aggregateprincipalamountofunsecurednotes": 250000,
    "unsecurednotesinterest": 0.07,
    "unsecurednotesmaturitydate": "March 2020",
    "issuanceofunsecurednotesdescription": "In conjunction with the issuance of the Unsecured Notes, the note holders were also issued a warrant to subscribe for $7,500 new PPL or Eygen ordinary shares for every $10,000 of principal issued, respectively, provided that a certain qualifying event occurs within the three years of issuance.",
    "financialliabilitiesatfairvalue": 24000,
    "convertiblenotesmature": 50000,
    "commonstockvalues": 116237000,
    "commonstockshares": 1085790000,
    "sharesissuedonacquisitionofsalvarxlimitedvalues": 92583000,
    "sharesissuedonacquisitionofsalvarxlimitedshares": 805070000,
    "stockoptionreserve": 324000,
    "optionsrelatingtopreacquisitionservices": 7364000,
    "optionlifeshareoptionsgranted": "P3Y2M12D",
    "fairvalueatmeasurementdatesharesoptionsgranted": 4630.35,
    "numberofoutstandingshareoption": 2599,
    "numberofshareoptionsacquisition": 2599000,
    "numberofshareoptionsgrantedinsharebasedpaymentsarrangement": 9341,
    "numberofshareoptionsexpiredinsharebasedpaymentsarrangement": -1250000,
    "numberofshareoptionsexercisableinsharebasedpaymentsarrangements": 1728000,
    "weightedaverageexercisepriceofshareoptionsexercisedinsharebasedpaymentarrangement2019": 152.84,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P3Y1M6D",
    "fairvalueofvestedioxoptionsacquired": 7400000,
    "stockoptionsissued": 595974,
    "descriptionofmaximumtermofoptionsgrantedforsharebasedpaymentarrangement": "The stock options vest quarterly over 4 years and expire in five years.",
    "expecteddividendshareoptionsgranted": 40000,
    "communicationexpense": 1200000,
    "sharesissueddescription": "Were issued under 2011 Consultant Stock Compensation Plan to six consultants including 1,390,000 to five directors, for services provided.",
    "applicabletaxrate": -0.17,
    "taxrateeffectofexpensenotdeductibleindeterminingtaxablestockbasedcompensation": 0.114,
    "taxrateeffectofexpensenotdeductibleindeterminingtaxableprofittaxloss": -0.002,
    "taxrateeffectfromchangeintaxrate": 0.058,
    "netoperatinglosscarryforwardatacquisitiondate": 252,
    "netoperatinglosscarryforwardpostacquisitions": 96,
    "valuationallowancefordeferredtaxasset": 348,
    "deferredtaxliabilitiesinprocessrandd": -20364,
    "researchanddevelopmentexpensecashcredits": 22000,
    "taxlossesdescription": "Tax losses for IOX were approximately $2.1 million (2018: nil). Tax losses for IOX acquired in the SalvaRx acquisition were $1.5 million and tax losses subsequent to the SalvaRx acquisition were $0.6 million.",
    "antidilutiveeffectstockoptionsincomputationofdilutedloss": 595842,
    "currentprepaymentsandcurrentaccruedincome": 73412,
    "prepaidexpensesandotherreceivables": 282000,
    "accountspayableandaccruedliabilities": 1107000,
    "warrantliability": 2475000,
    "fairvaluemarketpricepershare": 51.47,
    "payablesandaccruedexpense": 1100,
    "cashinhand": 6200,
    "acquisitiondatefairvaluesofnoncontrollinginterestsinsubsidiaries": 90000,
    "salvarxwarrantsvesteduponacquisition": 2451000,
    "vestedportionofioxstockoptions": 7364000,
    "stockbasedcompensationexpense": 1111000,
    "netlossattributabletononcontrollinginterest": -3000
  }
]